期刊文献+

小鼠Islet-1基因RNAi慢病毒载体的构建 被引量:3

Construction of RNAi lentiviral vector targeting mouse Islet-1 gene
下载PDF
导出
摘要 目的构建高效沉默小鼠Islet-1基因的慢病毒载体。方法针对小鼠Islet-1基因设计3个RNAi靶序列,合成相应的短发卡RNA(shRNA)寡核苷酸序列(oligo):Sh1、Sh2、Sh3,分别插入经酶切后的PLVTHM载体。经PCR和测序方法筛选阳性克隆,抽提阳性克隆质粒经大肠埃希菌扩增后,与其辅助包装质粒共同感染293T细胞制备慢病毒载体,利用斑形成试验测定病毒滴度。感染C3H10T1/2细胞株,以流式细胞仪检测其感染效率、荧光定量PCR检测其干扰效率。结果与正常C3H10T1/2细胞比较,测序及PCR结果显示目的片段插入正确;病毒滴度值为3.87×108TU/ml;慢病毒载体对C3H10T1/2细胞感染效率达90.36%;3个靶点(抑制效率分别为76.8%5、5.1%和11.7%)均有干扰效果,与正常细胞比较,Sh1靶点干扰效果最为显著(76.8%,P<0.05)。结论成功构建高效沉默Islet-1基因慢病毒载体。 Objective To construct and select RNAi lentiviral vectors that can silence mouse Islet-1 gene effectively.Methods Three groups of RNAi-target of mouse Islet-1 gene were designed,and corresponding shRNA oligo(sh1,sh2 and sh3) were synthesized,and then they were respectively inserted to the PLVTHM vector that had been digested by endonuclease.Agarose gel electrophoresis and sequencing were used to select and indentify the positive clones.The positive clones were extracted and then mixed with E.coli to amplify positive clones.The amplified clones were then infected into 293T along with the other 3 helper plasmids to produce lentiviral vector.After the construction of the lentiviral vector,plaque formation test was performed to determine the titer of lentiviral vector.The lentiviral vectors were then infected into C3H10T1/2 cells.The transfect efficiency of the lentiviral vectors was determined with flow cytometry with detection of green fluorescent protein(GFP).Q-PCR was employed to detect the RNAi efficiency of the lentiviral vectors.Results Agarose gel electrophoresis analysis showed that the clones with right gene at the target size were successfully established;gene sequencing showed that the right DNA fragments had been inserted;plaque formation test showed that the titer of the virus solution was 3.87×108TU/ml;the transfect efficiency of the lentiviral vector infected into C3H10T1/2 cells was 90.36%.All the 3 groups of shRNA targets(sh1,sh2 and sh3) showed an inhibitory effect on Islet-1 gene,and the sh1 showed the highest inhibitory effect(76.8%),as compared with that of normal cells(P〈0.05).Conclusion The RNAi lentiviral vector that can effectively silence the mouse Islet-1 gene has been constructed successfully,which may lay a foundation for further investigation of Islet-1 gene.
出处 《解放军医学杂志》 CAS CSCD 北大核心 2011年第2期170-173,共4页 Medical Journal of Chinese People's Liberation Army
基金 国家自然科学基金(30973219)
关键词 慢病毒感染 RNA干扰 基因 Islet-1 细胞分化 lentivirus infection; RNA interference; gene,Islet-1; cell differentiation;
  • 相关文献

参考文献5

  • 1朱静,邓兵,王金菊,田杰,王应雄.5-aza诱导干细胞经乙酰化特异RNAi后心肌细胞发育相关基因检测[J].第三军医大学学报,2006,28(6):535-538. 被引量:8
  • 2Genead R, Danielsson C, W rdell E, et al. Early first trimester hu man embryonic cardiac Islet-1 progenitor cells and cardiomyocytes Immunohistochemical and electrophysiological characterization[J].Stem Cell Res, 2010, 4(1) : 69- 76.
  • 3Bu L, Jiang X, Martin-Puig S, et al. Human ISL1 heart progenitors generate diverse multipotent cardiovascular ceil lineages[J]. Nature, 2009, 460(7251): 113- 117.
  • 4Moretti A, Bellin M, Jung CB, et al. Mouse and human induced plu ripotent stem cells as a source for multipotent Isll + cardiovascular progenitors[J]. FASEB J, 2010, 24(3) : 700- 711.
  • 5Lois C, Hong EJ, Pease S, et al. Germline transmission and tissue specific expression of transgenes delivered by lentiviral vectors[J].Science, 2002, 295(5556) : 868-872.

二级参考文献11

  • 1张文,田杰,江德勤,张蕾,朱静,陈沅.骨髓间充质干细胞体外分化为心肌样细胞相关调控基因的时序表达[J].中华心血管病杂志,2004,32(11):1004-1008. 被引量:25
  • 2REINLIB L,FIELD L.Cell transplantation as future therapy for cardiovascular disease:A workshop of the National Heart,Lung,and Blood Institute[J].Circulation,2000,101 (18):E182-E187.
  • 3GULBINS H,MEISER B M,REICHENSPURNER H,et al.Cell transplantation-a potential therapy for cardiac repair in the future[J] ?Heart Surg Forum,2002,5(4):E28 -E34.
  • 4PITTENGER M F,MACKAY A M,BECK S C,et al.Multilineage potential of adult human mesenehymal stem cells[J].Science,1999,284(5411):143-147.
  • 5FLETCHER T M,HANSEN J C.The nucleosomal array:structure/function relationships[J].Crit Rev Eukaryote Gene Expr,1996,6(2-3):149 -188.
  • 6BROWNELL J E,ZHOU J,RANALLI T,et al.Tetrahymena histone acetyltransferase A:a homolog to yeast GCN5p linking histone acetylation to gene activation[J].Cell,1996,84(6):843-851.
  • 7VENTURA C,MAIOLI M.Opioid peptide gene expression primes cardiogenesis in embryonal pluripotent stem cells[J].Circ Res,2000,87(3):189 -194.
  • 8NEMER G,NEMER M.Regulation of heart development and function through combinatorial interactions of transcription factors[J].Ann Med,2001,33(9):604-610.
  • 9KINGSTON R E,BUNKER C A,IMBALZANO A N.Repression and activation by multiprotein complexes that alter chromatin structure[J].Gnnes Dev,1996,10(8):905 -920.
  • 10VOLPE T A,KIDNER C,HALL I M,et al.Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by RNAi[J].Science,2002,297(5588):1833-1837.

共引文献7

同被引文献42

  • 1罗冰,王卫萍,刘明杰,王艾丽.荧光实时定量PCR检测前列腺癌抗原3评分方法的建立[J].医学研究生学报,2011,24(6):569-572. 被引量:1
  • 2Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis[J]. Cancer Res, 2001, 61(17): 6307-6312.
  • 3Romano M, Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy[J]. FASEB J, 2003, 17(14): 1986-1995.
  • 4Charames CS, Bapat B. Cycloocygenase-2 knockdown by RNA interference in colon cancer[J]. Int J Oncol, 2006, 28(2): 543-549.
  • 5Goossens L, Pommery N, Henichart JP. COX-2/5-LOX dual acting anti-inflammatory drugs in cancer chemotherapy[J]. Curr Top Med Chem, 2007, 7(3): 283-296.
  • 6Menna C, Olivieri F. Lipoxygenase inhibitors for cancer prevention: promises and risks[J]. Curr Pharm Des, 2010, 16(6): 725-733.
  • 7Fiorucci S, Meli R, Bucci M, et al.Dual inhibitors of cyclooxy-genase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy[J]? Biochem Pharmacol, 2001, 62(11):1433-1438.
  • 8Yao M, Zhou W, Sanqha S, et al. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer[J]. Clin Cancer Res, 2005, 11(4): 1618-1628.
  • 9Bias P, Buchner A, Klesser B, et al. The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial[J]. Am J Gastroenterol, 2004, 99(4): 611-618.
  • 10Layton D, Sorverein PC, Heerdink ER, et al. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in the Netherlands[J]. Drug Saf, 2008, 31(2): 143-158.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部